US Patent Issued to Board of Regents, The University of Texas System on July 8 for "Next generation FKBP52 targeting drugs for the treatment of prostate and breast cancer" (Canadian, American Inventors)

ALEXANDRIA, Va., July 9 -- United States Patent no. 12,351,560, issued on July 8, was assigned to Board of Regents, The University of Texas System (Austin, Texas).

"Next generation FKBP52 targeting drugs for the treatment of prostate and breast cancer" was invented by Marc Cox (El Paso, Texas), Artem Cherkasov (Vancouver, Canada) and Fuqiang Ban (Vancouver, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "Procedures for inhibiting hormone receptor activation include administering to a subject in need of hormone receptor inhibition a compound having a chemical structure of a molecule that, when docked in the PPIase pocket, could disrupt proline-rich loop conformation and interactions. Procedures for trea...